Cost Per Response Analysis of Nivolumab Versus Everolimus in the Treatment of Patients Previously Treated with Advanced Renal Cell Carcinoma – Brazil Private Health Care System Perspective
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.2579
https://www.valueinhealthjournal.com/article/S1098-3015(17)32913-3/fulltext
Section Title :
SELECTED HEALTH CARE TREATMENT STUDIES -MEDICAL DEVICE/DIAGNOSTICS
Section Order :
2375
First Page :
A875
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)32913-3&doi=10.1016/j.jval.2017.08.2579